ProBiotix Health expands in North America following licensing agreement with Genuine Health

January 26, 2021
Sebastian Krawiec

ProBiotix Health, a subsidiary of OptiBiotix Health PLC, has reached a non-exclusive licensing agreement for its branded LPLDL ingredient with Genuine Health for the development of a cardiovascular health product in Canada and the U.S.

ProBiotix Health, a subsidiary of OptiBiotix Health PLC (Heslington, York, UK), has reached a non-exclusive licensing agreement for its branded LPLDL ingredient with Genuine Health for the development of a cardiovascular health product in Canada and the U.S.

"We are pleased to have signed an agreement with Genuine Health in such an important market for probiotic products,” said Mikkel Hvid-Hansen, Commercial Director at ProBiotix, in a press release. “We believe working with the Canadian company creates a unique opportunity to achieve a probiotic health claim for cardiovascular health, while providing further product differentiation in the North American market.”

As part of the agreement, Genuine Health will submit its LPLDL products to Health Canada, and if registration is successful, LPLDL will be the first probiotic supplement in the Canadian market to obtain a specific health claim for cardiovascular health. "We are excited to work towards introducing innovative and science-backed products into the North American market through our relationship with ProBiotix,” said Stewart Brown, founder and CEO of Genuine Health, in a press release. “As such, we look forward to a long and successful partnership with ProBiotix Health."